Get the Daily Brief
Latest Biotech News
Illumina’s constellation reads: GeneDx pilot spots hard‑to‑see variants
Illumina’s new constellation map read technology was trialed with GeneDx to detect difficult‑to‑map genomic variants in rare‑disease samples. The pilot reportedly exceeded alternative methods in...
PacBio drives down genome costs — reusable SMRT cells target sub‑$300 genomes
Pacific Biosciences announced a new chemistry and a program to allow select customers to reuse SMRT cells, aiming to lower per‑genome consumable costs for large sequencing projects. PacBio...
RPI membrane outperforms chromatography — faster, cleaner mRNA purification
Researchers at Rensselaer Polytechnic Institute developed a regenerated cellulose membrane with peptide ligands that outperformed commercial chromatography columns for mRNA purification. The team...
Tempus wins $60M ARPA‑H contract for AI cancer biomarker work
The U.S. Department of Health and Human Services awarded Tempus AI a $60 million ARPA‑H contract to support testing and research using biomarkers to create adaptive treatment strategies for...
Create Medicines expands beyond myeloid programming — rebrands and broadens pipeline
Myeloid Therapeutics rebranded as Create Medicines and announced an expanded strategy to program multiple immune lineages in vivo using an mRNA‑LNP platform. The company said the pivot will add T...
Novo Nordisk bets $2.1B on Omeros’ MASP‑3 antibody: rare disease play
Novo Nordisk agreed to acquire global rights to zaltenibart, an Omeros antibody that inhibits MASP‑3, in a deal worth up to $2.1 billion including milestones. Novo will fund pivotal testing in...
Tubulis pulls record European series C — ADC program fueled for expansion
Antibody‑drug conjugate specialist Tubulis closed a €308 million (≈$356M) Series C to expand clinical development of TUB‑040 and its ADC platform. The funding positions the company to test its...
Kailera nets $600M to take Zepbound‑like obesity shot into global phase 3
Kailera Therapeutics closed a $600 million Series B led by Bain Capital PE to advance KAI‑9531, a weekly injectable targeting the same receptors as market leader GLP‑1/GIP agents, into global...
BioCryst snaps up Astria for $700M — doubles down on hereditary angioedema
BioCryst agreed to acquire Astria Therapeutics for roughly $700 million in cash and stock to add Astria’s long‑acting injectable navenibart to its hereditary angioedema (HAE) portfolio. The deal...
Long‑read sequencing: PacBio cuts genome costs with reusable SMRT cells
Pacific Biosciences unveiled a program enabling reuse of SMRT cell consumables and launched a new Sprq‑Nx chemistry that raises output and adds 5‑hydroxymethylcytosine detection. PacBio says...
In vivo programming and LNPs: Create Medicines expands, startups raise LNP capital
Myeloid Therapeutics rebranded as Create Medicines and broadened its in‑vivo immune programming strategy beyond myeloid cells to include T and NK cells using mRNA‑LNP platforms, aiming for...
Clinical genomics speeds to the bedside — hours‑long WGS and rapid RNA‑Seq services
Boston Children’s Hospital, Broad Clinical Labs and Roche Sequencing Solutions achieved a new record for ultra‑fast human whole‑genome sequencing optimized for NICU diagnostics, compressing...
ALS diagnostics and research: blood test emerges, molecular insights deepen
UCLA Health researchers reported a blood test that detects ALS rapidly by measuring circulating cell‑free DNA (cfDNA) signatures, offering a potential noninvasive diagnostic adjunct for earlier...
mRNA supply chain upgrades: cellulose membrane purification and CDMO capacity in India
Researchers at Rensselaer Polytechnic Institute developed a regenerated cellulose (RC) membrane with peptide ligands that outperformed chromatography columns for mRNA purification, offering...
Public‑health upheaval: CDC cuts and exodus from FDA leadership unsettle agencies
Mass layoffs and leadership departures at the US Centers for Disease Control and Prevention have culled an estimated quarter of the workforce this year, according to union tallies, affecting...
Novo Nordisk Licenses Omeros’ MASP‑3 drug: $2.1B deal
Novo Nordisk struck a definitive asset purchase and license agreement with Omeros for zaltenibart, an experimental MASP‑3 inhibitor, in a deal worth up to $2.1 billion including $340 million in...
Tubulis Raises €308M Series C — ADC program expansion
Antibody‑drug conjugate specialist Tubulis closed a large Series C financing—reported at roughly €308 million (about $356 million)—to accelerate clinical development of TUB‑040 and its ADC...
Pelage Collects $120M... Phase III for hair‑loss gel set
Pelage Pharmaceuticals closed an oversubscribed $120 million Series B to advance PP‑405, a topical regenerative small molecule intended to reactivate dormant hair follicle stem cells, into a...
Kailera Nets $600M Series B: Dual‑target obesity shot moves to Phase 3
Kailera Therapeutics closed a $600 million Series B led by Bain Capital Private Equity to support global Phase‑3 trials of KAI‑9531, a weekly injectable targeting the same dual receptor axis as...
Lilly Defends Oral GLP‑1: New data bolster orforglipron
Eli Lilly reported two additional late‑stage diabetes trial wins for orforglipron, an oral GLP‑1 receptor agonist, including superiority versus AstraZeneca’s Farxiga in glycemic control in Type 2...